Dziodzio T, Öllinger R, Schöning W, et al. - Researchers conducted this validation study to reproduce the diagnostic accuracy seen with the CreLIMAx risk score, which combines the LiMAx test with serum creatinine, in patients with end-stage liver disease. They included 113 patients suffering from liver cirrhosis and studied their liver function prospectively. Liver-related death within 12 months of follow-up was the primary end-point of the study. The main cause of liver disease in this study was alcoholic liver disease. MELD, MELD-Na and the CreLiMAx risk score showed similar measures of diagnostic accuracy for predicting short and medium-term mortality risk in the overall cohort. The CreLiMAx risk score was the only parameter significantly differing in non-survivors and survivors, in a subgroup analysis of patients with Child-Pugh Class B cirrhosis. The CreLiMAx risk score seems to be a competitive and valid tool for predicting survival in patients with end-stage liver disease. The new score showed a strong ability to recognize patients not at risk of death, especially in patients with Child-Pugh Class B cirrhosis.